Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Eli Lilly & Co., liquidity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The liquidity profile exhibits recurring cyclical fluctuations with a general strengthening trend emerging in 2025. A consistent pattern is observed where liquidity ratios peak in the first quarter and decline toward the end of the calendar year, suggesting seasonal working capital requirements or year-end balance sheet adjustments.

Current Ratio
The current ratio demonstrates a volatile but overall upward trajectory. After fluctuating between 1.05 and 1.30 throughout 2022 and 2023, the ratio reached a periodic low of 0.94 in December 2023. A significant recovery followed, with the ratio climbing to a peak of 1.58 by December 2025. Although a slight contraction to 1.35 is noted by June 2026, the overall capacity to cover short-term obligations with current assets has improved compared to the 2022-2023 period.
Quick Ratio
The quick ratio remains consistently below 1.0 across the entire analyzed period, indicating that current assets are heavily weighted toward inventory rather than more liquid assets. A downward trend was evident through 2023, hitting a minimum of 0.52 in December 2023. A marked improvement occurred during 2025, where the ratio climbed to a peak of 0.78 in December 2025, before stabilizing around 0.68 by mid-2026.
Cash Ratio
The cash ratio reflects a lean liquidity strategy, with values typically ranging between 0.09 and 0.24. The ratio experienced a gradual decline from 2022 through early 2025, reaching a low of 0.09 in June 2025. However, a sharp increase to 0.24 was recorded in September 2025, suggesting a significant cash infusion or strategic accumulation of liquid reserves, followed by a moderate decline and subsequent recovery to 0.19 by June 2026.

The widening gap between the current ratio and the quick ratio, particularly evident in 2025, highlights an increasing reliance on inventory to maintain overall liquidity. Despite the volatility in cash holdings, the general upward movement of all three ratios entering 2026 suggests an improved short-term financial position.


Current Ratio

Eli Lilly & Co., current ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity profile reflects a period of significant expansion in both current assets and current liabilities, with a notable shift toward a stronger liquidity position in the latter stages of the observed period. While a brief contraction in the short-term solvency margin occurred, subsequent asset growth outpaced the growth of liabilities, resulting in a strengthened current ratio by 2025 and 2026.

Current Asset Growth
Current assets exhibited a consistent upward trajectory, rising from 16,965 million US dollars in March 2022 to 64,672 million US dollars by June 2026. A period of accelerated expansion is evident starting in March 2024, as assets increased from 25,189 million US dollars to over 64,000 million US dollars within approximately two years.
Current Liability Trends
Current liabilities increased from 13,386 million US dollars in March 2022 to 47,741 million US dollars by June 2026, though this growth was less linear than that of assets. A significant contraction in liabilities occurred in March 2024, where the figure dropped to 18,598 million US dollars from a December 2023 peak of 27,293 million US dollars, before resuming an upward trend through 2026.
Current Ratio Analysis
The current ratio fluctuated between a low of 0.94 and a peak of 1.58. A period of liquidity pressure is observed in late 2023, with the ratio dipping to 0.94 in December 2023, marking the only instance where current liabilities exceeded current assets. A recovery followed in March 2024, with the ratio rising to 1.35. The most robust liquidity position was maintained between March 2025 and December 2025, during which the ratio remained above 1.28 and reached its maximum of 1.58 in December 2025.

Quick Ratio

Eli Lilly & Co., quick ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Accounts receivable
Other receivables
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Analysis of the liquidity position from March 2022 to June 2026 reveals a sustained period of balance sheet expansion characterized by significant increases in both quick assets and current liabilities. Despite the growth in absolute liquid resources, the quick ratio consistently remains below 1.0, indicating a reliance on other current assets or external financing to meet short-term obligations.

Total Quick Assets Trend
Quick assets exhibited a strong upward trajectory, growing from 10,265 million USD in March 2022 to 32,425 million USD by June 2026. This growth was non-linear, with a significant surge occurring between March 2025 and September 2025, where assets rose from 17,097 million USD to 29,249 million USD.
Current Liabilities Trajectory
Short-term obligations increased more aggressively than quick assets, rising from 13,386 million USD in March 2022 to 47,741 million USD by June 2026. This acceleration in liabilities is particularly evident in the final four quarters of the analyzed period, where current liabilities rose from 35,228 million USD in September 2025 to 47,741 million USD in June 2026.
Quick Ratio Analysis
The quick ratio demonstrated notable volatility, fluctuating between a minimum of 0.52 in December 2023 and a maximum of 0.79 in March 2023. A general decline was observed throughout 2022 and 2023, followed by a period of stabilization and a temporary recovery in late 2025, where the ratio peaked at 0.78 in December. The closing ratio of 0.68 in June 2026 confirms a persistent trend where quick assets cover approximately two-thirds of current liabilities.

Cash Ratio

Eli Lilly & Co., cash ratio calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio demonstrates a general trend of low liquidity throughout the analyzed period, reflecting a strategy where cash and cash equivalents are maintained at a small fraction of current liabilities. While the ratio experienced fluctuations, it predominantly remained below 0.20, indicating a heavy reliance on other current assets or external financing to meet short-term obligations.

Cash Ratio Trends
The cash ratio began at 0.18 in March 2022 and exhibited a downward trajectory, reaching a low of 0.09 by June 2025. A brief recovery occurred in March 2023 with a peak of 0.22, followed by a sustained period of compression. A significant upward shift was observed in September 2025, where the ratio reached its maximum of 0.24 before stabilizing between 0.14 and 0.19 through June 2026.
Current Liabilities Expansion
There is a consistent and substantial increase in current liabilities over the reported timeframe. Obligations grew from 13,386 million US$ in March 2022 to 47,741 million US$ by June 2026. This expansion was particularly aggressive between December 2023 and June 2026, where liabilities nearly doubled, placing continuous pressure on the liquidity ratio.
Cash Asset Volatility
Total cash assets remained relatively stable, fluctuating between approximately 2,000 million US$ and 3,500 million US$ for the majority of the period. However, a marked deviation occurred in the latter half of 2025, with assets spiking to 9,792 million US$ in September 2025. This surge drove the temporary increase in the cash ratio, although cash levels subsequently fluctuated between 5,282 million US$ and 8,950 million US$ in the following quarters.